DK2211183T3 - Fremgangsmåde til diagnosticering og overvågning af Alzheimer's sygdom - Google Patents

Fremgangsmåde til diagnosticering og overvågning af Alzheimer's sygdom

Info

Publication number
DK2211183T3
DK2211183T3 DK10002682.2T DK10002682T DK2211183T3 DK 2211183 T3 DK2211183 T3 DK 2211183T3 DK 10002682 T DK10002682 T DK 10002682T DK 2211183 T3 DK2211183 T3 DK 2211183T3
Authority
DK
Denmark
Prior art keywords
diagnosing
disease
monitoring alzheimer
alzheimer
monitoring
Prior art date
Application number
DK10002682.2T
Other languages
English (en)
Inventor
Anton Wyss-Coray
Sandip Ray
Original Assignee
Satoris Inc
Univ Leland Stanford Junior
U S Government Represented By The Dept Of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Satoris Inc, Univ Leland Stanford Junior, U S Government Represented By The Dept Of Veterans Affairs filed Critical Satoris Inc
Application granted granted Critical
Publication of DK2211183T3 publication Critical patent/DK2211183T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK10002682.2T 2003-11-19 2004-11-19 Fremgangsmåde til diagnosticering og overvågning af Alzheimer's sygdom DK2211183T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US52379603P 2003-11-19 2003-11-19
US56678204P 2004-04-30 2004-04-30
US56678304P 2004-04-30 2004-04-30
EP04811912A EP1692520A2 (en) 2003-11-19 2004-11-19 Method for diagnosis, stratification and monitoring of alzheimer's disease

Publications (1)

Publication Number Publication Date
DK2211183T3 true DK2211183T3 (da) 2013-05-13

Family

ID=34637169

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10002682.2T DK2211183T3 (da) 2003-11-19 2004-11-19 Fremgangsmåde til diagnosticering og overvågning af Alzheimer's sygdom

Country Status (9)

Country Link
US (1) US7598049B2 (da)
EP (2) EP1692520A2 (da)
JP (1) JP2007513337A (da)
AU (1) AU2004294178C1 (da)
CA (1) CA2546461A1 (da)
DK (1) DK2211183T3 (da)
ES (1) ES2411455T3 (da)
PT (1) PT2211183E (da)
WO (1) WO2005052592A2 (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
US7598049B2 (en) 2003-11-19 2009-10-06 Satoris, Inc. Methods for diagnosis of Alzheimer's Disease in blood samples
WO2006091453A1 (en) * 2005-02-18 2006-08-31 The Research Foundation Of State University Of New York Blood c5a levels as an indicator of rhinoconjunctivitis severity
US8078275B2 (en) 2005-04-15 2011-12-13 Functional Neuromodulation Inc. Regulation of neurotrophins
WO2007059135A2 (en) * 2005-11-10 2007-05-24 Satoris, Inc. Methods of treating alzheimer's disease
US9770485B2 (en) * 2006-02-21 2017-09-26 Academia Sinica Methods for rescuing learning and/or memory deficits caused by alzheimer's disease by G-CSF
DE102006023175A1 (de) * 2006-05-17 2007-11-22 B.R.A.H.M.S Aktiengesellschaft In vitro Verfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
US7851172B2 (en) * 2006-07-25 2010-12-14 University Of Kentucky Research Foundation Biomarkers of mild cognitive impairment and alzheimer's disease
US20090099783A1 (en) * 2007-06-08 2009-04-16 Barry Reisberg Stage Specific Prognostic In Vivo Markers of Brain Aging and Dementia
JP5309151B2 (ja) * 2007-11-14 2013-10-09 カーディアック ペースメイカーズ， インコーポレイテッド 神経治療用システム
SG10201704689XA (en) 2008-01-18 2017-07-28 Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
AU2009219406A1 (en) * 2008-02-27 2009-09-03 Avid Radiopharmaceuticals, Inc. Gamma probe detection of amyloid plaque using radiolabeled A-beta binding compounds
CA2718955C (en) 2008-03-21 2015-10-13 Manuela G. Neuman Methods and kits for the differential diagnosis of alzheimer's disease versus frontotemporal dementia and for the diagnosis of frontotemporal dementia comprising fas-l and ck 18 as biomarkers
JP5419138B2 (ja) * 2009-03-27 2014-02-19 Ｎｅｃソフト株式会社 検出対象物の検出方法およびそれに用いる検出用キット
JP2010271078A (ja) 2009-05-19 2010-12-02 Mcbi:Kk 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法
US9493834B2 (en) 2009-07-29 2016-11-15 Pharnext Method for detecting a panel of biomarkers
US20110070242A1 (en) * 2009-09-01 2011-03-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for Diagnosing and Treating Iron Dysregulation
US20130116135A1 (en) * 2009-11-24 2013-05-09 Commonweath Scientific And Industrial Research Organisation Methods, Kits and Reagents for Diagnosing, Alding Diagnosis and/or Monitoring Progression of a Neurological Disorder
WO2017120461A1 (en) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US20110202284A1 (en) * 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
WO2011103308A2 (en) * 2010-02-17 2011-08-25 U.S. Department Of Veteran Affairs Methods of using human protein kinase c delta viii as a biomarker
GB201005456D0 (en) * 2010-03-31 2010-05-19 Cambridge Entpr Ltd Biomarkers
MX2013000917A (es) 2010-07-23 2013-07-05 Harvard College Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
SG10201505723UA (en) 2010-07-23 2015-09-29 Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
WO2012083034A1 (en) * 2010-12-15 2012-06-21 Louis Sanfilippo Modulation of neurotrophic factors by omega-3 fatty acid formulations
US20120251524A1 (en) * 2011-04-01 2012-10-04 Baxter Healthcare S.A. Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
US20150168422A1 (en) * 2011-05-12 2015-06-18 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9927445B2 (en) * 2011-05-18 2018-03-27 Balwant Rai Biomarkers for prediction, diagnosis, and monitoring of parkinson's disease
US9529002B2 (en) * 2011-05-18 2016-12-27 Balwant Rai Biomarkers for prediction, diagnosis, and monitoring of Alzheimer's disease
WO2013022953A2 (en) * 2011-08-08 2013-02-14 Eugenia Wang Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
JP5814800B2 (ja) * 2011-12-28 2015-11-17 株式会社Ｌｓｉメディエンス 神経変性疾患の検出方法
EP3255435A1 (en) 2012-04-13 2017-12-13 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
EA201590024A1 (ru) 2012-06-15 2015-05-29 Гарри Стилли Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
CN104603289A (zh) 2012-06-15 2015-05-06 哈里·斯泰利 检测疾病或病状的方法
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
CA3206342A1 (en) 2013-05-09 2014-11-13 Advanced Neuroregenerative Therapies, Llc G-csf for use in treating or preventing a disease with age and disease immune dysfunction and cellular senescence
WO2015006489A1 (en) * 2013-07-11 2015-01-15 University Of North Texas Health Science Center At Fort Worth Blood-based screen for detecting neurological disease in primary care settings
US20190219599A1 (en) * 2013-07-11 2019-07-18 University Of North Texas Health Science Center At Fort Worth Blood-based screen for detecting neurological diseases in primary care settings
EP3074525B1 (en) * 2013-11-26 2024-06-26 University of North Texas Health Science Center at Fort Worth Personalized medicine approach for treating cognitive loss
EP3079708A4 (en) 2013-12-09 2017-08-30 The Board of Trustees of the Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
GB201322094D0 (en) * 2013-12-13 2014-01-29 Electrophoretics Ltd Methods and compositions relating to alzheimers disease
EP2899543A1 (en) 2014-01-28 2015-07-29 Predemtec GmbH Biomarker and methods for early diagnosis of Alzheimer's disease
WO2015168322A1 (en) * 2014-04-29 2015-11-05 Douglas Seals Methods for treatment of motor and cognitive functions using sodium nitrite
EP4428251A3 (en) 2014-09-11 2024-12-18 Immunis.AI, Inc. Methods of detecting prostate cancer
BR112017005730B1 (pt) 2014-09-26 2023-12-12 Somalogic Operating Co., Inc Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento
WO2016069461A1 (en) * 2014-10-27 2016-05-06 The Trustees Of The University Of Pennsylvania A parkinson's disease diagnostic biomarker panel
PT3307296T (pt) 2015-06-15 2022-01-07 Univ Leland Stanford Junior Timp2 para uso no tratamento de condições associadas ao envelhecimento
EP3426265B1 (en) 2016-04-28 2021-09-22 Alkahest, Inc. Plasma fractions as therapy for tumor growth and progression
IL304946A (en) 2016-08-18 2023-10-01 Alkahest Inc Blood plasma fractions as a treatment for cognitive disorders associated with aging
EA039316B1 (ru) 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
BR112019022402A2 (pt) 2017-04-26 2020-05-19 Alkahest Inc regime de dosagem para tratamento de comprometimentos cognitivo e motor com plasma sanguíneo e produtos de plasma sanguíneo
JP7412003B2 (ja) 2018-01-18 2024-01-12 ユニバーシティー オブ ノース テキサス ヘルス サイエンス センター アット フォートワース アルツハイマー病に罹患している患者の特定の亜集団を治療するためのｎｓａｉｄ及びドネペジルについてのコンパニオン診断
WO2019169049A1 (en) * 2018-02-28 2019-09-06 Human Longevity, Inc. Multimodal modeling systems and methods for predicting and managing dementia risk for individuals
MX2021004755A (es) 2018-10-26 2021-06-08 Alkahest Inc Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
CA3196988A1 (en) * 2020-10-30 2022-05-05 Baseline Bioscience, Inc. Methods, systems, and kits for prediction, detection, monitoring, and treatment of alzheimer's disease
CN116298233A (zh) * 2022-03-16 2023-06-23 昱言科技(北京)有限公司 用于诊断双相障碍的生物标记物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728605A (en) 1984-07-31 1988-03-01 Fudenberg Herman H Methods for recognizing and diagnosing subsets of Alzheimer's disease associated with immune system dysfunction, and for the in vitro testing of possible therapeutic agents for treatment of same
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
CA2142300C (en) 1992-10-13 2005-08-23 Allen D. Roses Methods for detecting alzheimer's disease
WO1995033992A1 (en) 1994-06-09 1995-12-14 Bar-Ilan University Diagnosis of alzheimer disease stage by mononuclear cell cytokine secretions
US5686269A (en) 1994-07-28 1997-11-11 The Mclean Hospital Corporation Method of diagnosing Alzheimer's disease by detecting the level of cathepsin D in cerebrospinal fluid
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
EP0817842A1 (en) 1995-03-24 1998-01-14 Takeda Chemical Industries, Ltd. Antibody to human betacellulin and use thereof
AUPO943297A0 (en) 1997-09-24 1997-10-16 University Of Melbourne, The Diagnostic test for alzheimer's disease
US6358681B2 (en) 1998-10-30 2002-03-19 The Trustees Of The University Of Pennsylvania Diagnostic methods for alzheimer's disease by detection of multiple mRNAs
JP4215857B2 (ja) * 1998-03-26 2009-01-28 裕 大村 学習・記憶能力改善剤
CA2269432C (en) 1998-06-01 2002-04-02 Hyman M. Schipper Ho-1 as a diagnostic and prognostic test for dementing diseases
WO2000002053A2 (en) * 1998-07-03 2000-01-13 Innogenetics N.V. Differential diagnosis of neurodegeneration
EP1050758A1 (en) * 1999-05-03 2000-11-08 Evotec BioSystems AG Methods of diagnosing or treating neuropsychiatric diseases on basis of increased cerebrospinal fluid levels of neurotrophin 3
US6692918B2 (en) 1999-09-13 2004-02-17 Nugen Technologies, Inc. Methods and compositions for linear isothermal amplification of polynucleotide sequences
ATE262595T1 (de) 1999-09-13 2004-04-15 Nugen Technologies Inc Methoden und zusammensetzungen zur linearen isothermalen amplifikation von polynukleotidsequenzen
US6699677B1 (en) 1999-12-20 2004-03-02 Chemocentryx, Inc. Tethered ligands and methods of use
US6465195B2 (en) 1999-12-30 2002-10-15 Washington University Predictive diagnostic for Alzheimer's disease
FR2816411B1 (fr) * 2000-11-03 2003-07-04 Inst Nat Sante Rech Med Moyens de detection de la transformation pathologique de la proteine app et leurs applications
EP1221618A1 (en) 2000-11-29 2002-07-10 GeneScan Europe AG Method for diagnosing allergic diseases
US6495335B2 (en) 2000-12-07 2002-12-17 Mario Chojkier Compositions and methods for diagnosing alzheimer's disease
US6475161B2 (en) 2001-03-29 2002-11-05 The Mclean Hospital Corporation Methods for diagnosing Alzheimer's disease and other forms of dementia
CA2446886A1 (en) * 2001-04-06 2002-10-17 Biovision Ag Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
US7070945B2 (en) 2001-04-25 2006-07-04 Syn X Pharma, Inc. Process for determining the presence of monomeric brain associated human glutamine synthetase in patients exhibiting mild cognitive impairment
US6451547B1 (en) 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor
US7608406B2 (en) 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20030119074A1 (en) 2001-12-20 2003-06-26 George Jackowski Diagnosis and treatment of dementia utilizing thrombospondin
US20060094064A1 (en) 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
US7598049B2 (en) 2003-11-19 2009-10-06 Satoris, Inc. Methods for diagnosis of Alzheimer's Disease in blood samples

Also Published As

Publication number Publication date
EP2211183B1 (en) 2013-03-06
PT2211183E (pt) 2013-05-31
WO2005052592A3 (en) 2005-09-29
AU2004294178B2 (en) 2011-06-09
JP2007513337A (ja) 2007-05-24
WO2005052592A2 (en) 2005-06-09
US7598049B2 (en) 2009-10-06
CA2546461A1 (en) 2005-06-09
AU2004294178A1 (en) 2005-06-09
US20050221348A1 (en) 2005-10-06
EP1692520A2 (en) 2006-08-23
EP2211183A1 (en) 2010-07-28
AU2004294178C1 (en) 2011-10-27
ES2411455T3 (es) 2013-07-05

Similar Documents

Publication Publication Date Title
DE602004019373D1 (de) Bilderzeugungsverfahren
BRPI0313238A2 (pt) método
EP1697308A4 (en) PHENYLAMID AND PYRIDYLAMIDE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
NO20032220D0 (no) Löfteverktöy II og fremgangsmåte for anvendelse av samme
DE60305762D1 (de) Abbildungsgerät und -verfahren
DE60320710D1 (de) Überwachungssystem, -verfahren und Bilderzeugungsgerät
DK1549385T3 (da) Prøvetagerhætte
DE60319191D1 (de) Brückenvorrichtung und -verfahren
DE60328144D1 (de) Bilderzeugende Vorrichtung
DE602004026179D1 (de) Programmempfehlungsverfahren
FI20020780A7 (fi) Menetelmä kullan talteenottamiseksi
DK1359593T3 (da) SPM-sensor og fremgangsmåde til dens fremstilling
EP1811063A4 (en) METHOD FOR THE GALVANIC DEPOSITION OF TIN-ZINC ALLOY
DE60317723D1 (de) Leseverfahren, Responder und Lesegerät
ATE345036T1 (de) Giessvorrichtung und -verfahren
FI20031083A0 (fi) Menetelmä rikasteiden aikaansaamiseksi
DE50306455D1 (de) Sensoreinrichtung sowie Montageverfahren für eine Sensoreinrichtung
EP1693671A4 (en) METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE
DE10295563D2 (de) Vorrichtung für eine Gehhilfe
DE60336113D1 (de) Aufzeichnungsverfahren
DE60328937D1 (de) Objektivdiagnostik
FI20020916A0 (fi) Tapahtumapohjainen raportointimenetelmä
NO20026027D0 (no) Metode for MR-undersökelser
NO20015802D0 (no) Diagnostisk metode
ITMI20030002A1 (it) Metodo e dispositivo per la verifica di funzionalita'